Prime Medicine (PRME) Accounts Payables (2021 - 2026)
Prime Medicine's (PRME) quarterly Accounts Payables came in at $12.3 million in Q1 2026, up 22.94% YoY from $10.0 million in Q1 2025, and up 38.69% on a QoQ basis from $8.9 million in Q4 2025.
Prime Medicine (PRME) Accounts Payables (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Accounts Payables data on file, last reported at $12.3 million in Q1 2026.
- Quarterly Accounts Payables rose 22.94% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 22.94% YoY) and the FY2025 annual result came in at $8.9 million, down 21.71% from the prior year.
- Accounts Payables advanced to $12.3 million in Q1 2026, from $8.9 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $19.5 million in Q4 2023 to a low of $4.1 million in Q3 2022.
- A 5-year average of $8.7 million and a median of $8.9 million in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables soared 350.99% — and 2024, when it slumped 61.56%.
- Tracing PRME's Accounts Payables over 5 years: stood at $4.3 million in 2022, then soared by 350.99% to $19.5 million in 2023, then slumped by 41.9% to $11.4 million in 2024, then retreated by 21.71% to $8.9 million in 2025, then jumped by 38.69% to $12.3 million in 2026.
- The last three Accounts Payables figures came in at $12.3 million (Q1 2026), $8.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 5.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.81 Mn |
| Mar 31, 2026 | 12.33 Mn |
| Dec 31, 2025 | 8.89 Mn |
| Sep 30, 2025 | 9.35 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 10.03 Mn |
| Dec 31, 2024 | 11.35 Mn |
| Sep 30, 2024 | 5.43 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Mar 31, 2024 | 10.08 Mn |
| Dec 31, 2023 | 19.54 Mn |
| Sep 30, 2023 | 14.12 Mn |
| Jun 30, 2023 | 5.49 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 4.33 Mn |
| Sep 30, 2022 | 4.11 Mn |
| Dec 31, 2021 | 1.44 Mn |